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Summary 
 
Interleukin (IL)-36 cytokines are new members of the IL-1 family, that include pro-
inflammatory factors, IL-36α, IL-36β and IL-36γ, and a natural receptor antagonist IL-36Ra. 
IL-36 cytokines are expressed in a specific manner by monocytes/macrophages, dendritic 
cells (DCs), T cells subsets, keratinocytes, Langerhans cells, and mucosal epithelium. Since 
IL-36 cytokines are predominantly expressed in keratinocytes it is not surprising that 
specifically skin disorders have been explored for associations with these cytokines. Several 
reports have found that IL-36α and IL-36γ are up-regulated in psoriatic and allergic contact 
dermatitis skin. Over recent years much has been learned on their important functions in the 
regulation of immune response and, especially, on their involvement in many inflammatory 
conditions. In this study, we wanted to elucidate the role of these mediators in the 
pathogenesis of most common inflammatory skin diseases such as, psoriasis, allergic contact 
dermatitis and polymorphic light eruption.  
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I CHAPTER 
IL-36 cytokines 
The interleukins (IL)-36 are members of the IL-1 superfamily, including 3 agonistic 
cytokines, namely IL-36α, IL-36β and IL-36γ, previously known as IL-1F6, IL-1F8, and IL-
1F9, and a natural inhibitor, IL-36Ra, previously termed IL-1F5. IL-36 were originally 
identified by a number of groups simultaneously through analysis of the human genome in 
search of gene sequences predicted to encode homologs of IL-1.
1–5
  IL-36α, β, γ elicit their 
proinflammatory effects through binding IL-36R, which subsequently forms a heterodimer 
with the IL-1R accessory protein (IL-1RAcP) to activate intracellular signaling pathways. 
The IL-1RAcP is also shared by the related IL-1 family receptors for IL-33 and IL-1α/β, with 
the IL-36R chain alone responsible for ligand specificity. Similar to these related receptors, 
the IL-36R chain is composed of an extracellular ligand-binding domain, a transmembrane 
helix, and an intracellular Toll/IL-1 receptor (TIR) domain required for the initiation of 
intracellular signaling cascades.
6
 The extracellular portion consists of three Ig-like domains, 
and the specific residues required for ligand binding have recently been identified.
7
 Upon 
activation, the IL-36R initiates distinct signaling pathways through the recruitment of the 
MyD88 adaptor protein to TIR domains present on both the IL-36R and IL-1RAcP. As with 
other IL-1 family members, this leads to the subsequent activation of the MAPK pathways 
mediated by JNK and ERK1/2, as well as NF-KB–dependent transcription, which combine to 
promote proinflammatory gene expression.
8
 
Similarly, IL-36Ra binds to IL-36R, but it prevents binding of IL-36α, IL-36β, and IL-36γ. 
Recent structural analysis of how IL-36Ra interacts with the receptor complex indicate that it 
acts as a classical antagonist through competitive binding to the extracellular Ig domains of 
the IL-36R chain, thereby preventing ligand binding and subsequent recruitment of the IL-
1RAcP.
7,9
 As a result, no downstream signaling is initiated through the IL-36R. Furthermore, 
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it has also been demonstrated that another IL-1 family member, IL-38, can also directly bind 
and act as an antagonist of the IL-36R.
10
  
 
 
The IL-36 cytokines are clustered on human chromosome 2 in the same locus that includes 
the genes for all other IL-1 family cytokines except for IL-18 and IL-33. The IL-36R also lies 
in the IL-1R family locus on human chromosome 2 and is flanked by IL-1R1 and IL-1R2 on 
the centromeric side and IL-33R, IL-18R, and IL-18RAP (accessory protein) on the telomeric 
side.
11-13 
IL-36 cytokines, such as all IL-1 family members except for IL- 1Ra, are 
synthesized without a signal peptide and therefore, are not secreted via the endoplasmic 
reticulum-Golgi pathway. It is unclear how IL-36 cytokines are released from cells; however, 
it is clear that post-translational processing is required for full agonist or antagonist activity 
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of all IL-36 members.
14
 Truncation of IL-36 members must occur at precisely the right 
location to generate the active form, whereas removal of 1 more or less amino acids results in 
a protein with activity comparable with the full-length protein. The enzyme or enzymes 
required for processing of IL-36 cytokines are unknown, and there are no aspartate residues 
or other features suggesting a cleavage site for caspase-1.
12,13
 IL-36 family cytokines are 
expressed in several tissues and by various immune and parenchymal cell subsets. Individual 
IL-36 cytokines are expressed in a specific manner by monocytes/macrophages, dendritic 
cells (DCs), T cells subsets, keratinocytes, Langerhans cells, and mucosal epithelium.
15-17
 
They are strongly up-regulated in the skin by many agents, including cytokines, TLR 
agonists, or by pathologic conditions. Indeed, IL-36α and γ are highly expressed in inflamed 
skin from psoriasis patients,
18-20
 as well as lesional skin from patients with atopic dermatitis. 
Furthermore, expression of IL-36α, β, and γ has been described in colonic epithelial cells 
from patients with inflammatory bowel disease (IBD),
21,22 
whereas IL-36γ expression is 
strongly induced in bronchial epithelium exposed to inflammatory stimuli.
23
  
 
IL-36 and their immune function 
 
IL-36 cytokines act as a crucial link in translating innate immune responses into the 
appropriate adaptive immune response. In particular, IL-36 exerts strong stimulatory effects 
on dendritic cells (DCs) and T-cells that play a critical role in the interface between innate 
and adaptive immune responses.
24
 IL-36 agonists are expressed by murine DC subsets in 
response to inflammatory stimuli; in addition they promote the maturation of DCs, up-
regulating markers of activation such as CD80, CD86 and MHCII.
16
 Murine as well as 
human DC subsets have been shown to express IL-36R and respond to stimulation with IL-36 
ligands.
16,25 
In contrast to IL-1, IL-36 can provide a relatively potent proinflammatory 
stimulus to murine bone marrow–derived DCs, leading to the induced expression of 
chemokines, such as CXCL1, CCL1, CXCL10, and CCL3, as well as proinflammatory 
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cytokines, including TNFα, IL-6, and granulocyte-macrophage colony-stimulating factor26. 
IL-36α and IL-36β are constitutively expressed by human and murine T cells, respectively16. 
Regarding IL-36R expression, there is an important difference between human and mouse 
cells.
27
 Indeed, mouse T cells express IL-36R and respond directly and indirectly to IL-36 
stimulation. IL-36α, IL-36β, and IL-36γ have a direct effect on mouse CD4+ T cells and 
splenocytes, inducing proinflammatory citokines.
16
 In addition, IL-36 has a role in the 
induction of T cell polarization. IL-36β, like IL-18, acts in combination with IL-12 to induce 
the in vitro differentiation of Th0 cells into IFNγ-producing Th1 cells.26 The influence of IL-
36 on Th1differentiation is completely dependent on IL-2 induction. In contrast, the effect of 
IL-36 on Th0 cell proliferation and survival is largely independent of IL-2.
28
 Vigne et al
.
 also 
demonstrated that CD4+ T cells constitutively express IL-36β, which can act in an autocrine 
fashion to promote cell survival as well as Th1 differentiation. Although IL-36 cytokines can 
potently induce Th1 responses, they do not appear to play a significant role in the host 
response to mycotic  infection. Human peripheral blood mononuclear cells that are stimulated 
with C. albicans, a potent inducer of the Th17 response in humans, produce less IL-17 and 
IL-22 in the presence of IL-36Ra.
10
 IL-36 cytokines can modulate the immune system 
primarily through their effects on antigen-presenting cells, such as DCs and in this way can 
polarize T helper responses.
26
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II CHAPTER  
IL-36 and diseases 
Unsurprisingly, in tandem with the emergence of data identifying the proinflammatory 
mechanisms through which IL-36 family members exert their effects, evidence of their 
central role as regulators of inflammatory disease has begun to accumulate.
29
 Indeed, IL-36 
might also play a significant role in joint disease. Remarkably, IL-36β is expressed in mouse 
and human joints
30 
and IL-36α was found to be up regulated in joints of patients with 
psoriatic and rheumatoid arthritis. Anyhow, no differences were detected for IL-36β at serum 
level between healthy human volunteers, and subjects affected by RA. A potential role for the 
IL-36 family as mediators of intestinal inflammation in the context of  inflammatory bowel 
disease (IBD) has also recently emerged.
31
 In contrast to the skin, where IL-36 appears to act 
exclusively in a proinflammatory capacity, the role of these cytokines in the gut appears more 
complex. Preliminary data provide evidence that IL-36 cytokines might play a role in obesity. 
Indeed, IL-36Ra is also expressed in differentiated pre-adipocytes, and can be downregulated 
by TNF-α, a proinflammatory cytokine.32Moreover, IL-36α and IL-36β can induce the 
expression  of  pro-inflammatory genes in mature adipocytes.
33 
Accumulating data also 
indicate that IL-36 family members may play a prominent role also in inflammatory diseases 
in the lung.
34
  
 
 
IL-36 and skin diseases 
Since IL-36 cytokines are predominantly expressed in epithelial cells and in particularly in  
keratinocytes it is not surprising that different skin disorders have been explored for 
associations with these cytokines. Several reports have found that IL-36α and IL-36γ were 
up-regulated in psoriatic skin lesions,
 35-37 
and there was a strong correlation with expression 
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of other cytokines, including IL-17, IL-23, TNF-α, and IFN-γ.38 Following these 
observations, several groups developed genetic mouse models to investigate whether and 
what role the IL-36 family might play in the pathogenesis of psoriasis. Initially, Blumberg et 
al.
33 
demonstrated that transgenic mice overexpressing IL-36α in keratinocytes have a strong 
skin phenotype at birth that resolves at weaning. This phenotype is abrogated when 
transgenic mice are crossed with IL-36R- or AcP-deficient mice but strongly exacerbated 
when IL-36a transgenic mice are crossed with IL-36Ra-deficient mice.
19
 Phorbol ester 
treatment of mouse skin overexpressing IL-36α results in an inflammatory condition with 
macroscopic and histological similarities to human psoriasis.
39
 One of the most compelling 
lines of evidence for a role of IL-36 as a driver of skin inflammation was obtained by 
engrafting immunodeficient mice with human psoriasis skin. Treatment of these mice with an 
anti-human IL-36R-neutralizing mAb led to substantial normalization of skin pathology.
39
 
Although the expression of IL-36Ra by IL-17-stimulated keratinocytes derived from patients 
with psoriasis does not differ from healthy controls,
40 
increased expression of the IL-36 
cytokines correlates with Th17 cytokines in human psoriatic skin lesions 
41 
and increased 
activation of MAPK and NF-kB.
42
  These results indicate that IL-36 may play an important 
role in psoriasis, as well as in other inflammatory diseases. In addition to psoriasis, the role of 
IL-36 has been studied in the pathogenesis of allergic contact dermatitis.
37
 Our group have 
demonstrated that gene expression of all 3 IL-36 agonists, but not IL-36Ra, was enhanced in 
ACD-involved skin. In addition ex vivo model showed that the addition of recombinant IL-
36RA, in skin explants, causes the reduction of IL-36α, IL-36β e IL-36γ gene expression.43 
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Pathogenesis of psoriasis 
Psoriasis is a common chronic inflammatory skin disease with characteristic, sharply 
demarcated erythematosquamous plaques restricted to distinct sites or disseminated over the 
skin surface.
44
 With a frequency of 2.5% in the Caucasian population psoriasis is one of the 
most common chronic inflammatory skin diseases of man.
45
 Approximately 10–30% of 
patients with psoriasis develop psoriatic arthritis (PsA).
46
 Psoriasis can be provoked by non-
specific triggers such as mild trauma (scratching, piercings, and tattoos), sunburn, or 
chemical irritants. The major histological traits of psoriasis encompass acanthosis and 
hyperkeratosis of the epidermis, elongation of dermal capillary vessels and a 
lymphohistiocytic inflammation which are clinically reflected by erythema, infiltration and 
scaling. Underlying major pathogenic traits have been allocated to a heterogenous 
(immuno)genetic background with a number of environmental and endogenous factors which 
result in a cellular and cytokine imbalance.
 44
Therefore, rather than viewing psoriasis as a 
disease caused by a single cell type or a single inflammatory cytokine, it is probably best to 
conceptualize its pathogenesis as linked to many interactive responses between infiltrating 
leucocytes, resident skin cells, and an array of proinflammatory cytokines, chemokines, and 
chemical mediators produced in the skin under regulation of the cellular immune system.
47
 
Psoriasis is mainly a dendritic cells (DCs) and T-cell-mediated disease with complex 
feedback loops from antigen-presenting cells, neutrophilic granulocytes, keratinocytes, 
vascular endothelial cells, and the cutaneous nervous system.
48
 Cross-talk between the innate 
and the adaptive immune system mediated by cytokines including TNFα, interferon γ, and 
interleukin 1 is a major research focus.
49
 TNFα is a pro-inflammatory cytokine that amplifies 
inflammation through several distinct pathways. TNFα is produced by a broad range of cell 
types including macrophages, lymphocytes, keratinocytes, and endothelial cells, and exerts 
its activities on several different cell types.
50
 TNFα induces secondary mediators and 
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adhesion molecules, all of which have been implicated in psoriatic disease. The clinical 
success of TNF-blocking agents is therefore not surprising.
51 
DCs, the most potent APCs 
(antigen-presenting cells), are sentinels of the immune system. In normal skin, DCs are found 
in the epidermis [LCs (Langerhans cells)] and dermis (myeloid and plasmacytoid DCs). LCs 
reside in the suprabasal layers of the epidermis in close contact with keratinocytes. After 
activation, LCs up-regulate chemokine receptors on their surface and migrate to skin-draining 
lymph nodes, where they present antigenic peptides they have encountered in the skin to 
naïve T-cells. The mobilization of LCs into draining lymph nodes in response to stimuli that 
normally induce migration [e.g. chemical allergen, TNF-α and IL -1β] is largely absent in 
psoriasis.
52
 There are also increased numbers of plasmacytoid DCs in psoriatic skin 
compared with normal skin.
53
 These express TLR (Toll-like receptor) 9 and produce large 
amounts of IFN (inteferon)-α when activated with the microbicidal cathelicidin LL37 bound 
to self-DNA fragments released by stressed or dying cells in the skin. Plasmacytoid DC also 
express TLR8 and make IFN-α when stimulated with self-RNA–LL37 complexes. LL37 can 
also bind self-RNA released by dying cells, and these complexes activate TLR7 in 
plasmacytoid DCs and, like self-DNA–LL37 complexes, trigger the secretion of IFN-α. In 
contrast with self-DNA–LL37 complexes, self-RNA–LL37 complexes can interact with 
TLR8 on classical myeloid DCs and promote their differentiation into mature DCs with 
secretion of TNF-α and IL-6. 52,53 
In psoriatic epidermis, keratinocytes proliferate and mature rapidly so that terminal 
differentiation, normally occurring in granular keratinocytes and then squamous corneocytes, 
is incomplete. Hence, squamous keratinocytes aberrantly retain intact nuclei (parakeratosis) 
and release few extracellular lipids that normally cement adhesions of 
corneocytes.
44
Accordingly, poorly adherent stratum corneum is formed and this results in the 
characteristic scale or flakes of psoriasis lesions. Increased numbers of T lymphocytes are a 
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highly consistent finding in psoriasis biopsies. With immunohistochemical staining, T 
lymphocytes are found interspersed between keratinocytes throughout the epidermis and in 
somewhat larger quantities in the dermis.
54-56
 
 
 
 
 
 
Complex dysregulation of almost every cutaneous cell type, which includes proliferation and 
cytokine production by epidermal keratinocytes, is affected by the TNFα pathway and 
interleukin-23/Th17 axis pathway. Furthermore, antimicrobial peptides, cytokines and 
chemokines secreted by keratinocytes act as chemoattractants for infiltrating immune cells.
57 
Thus, a positive feedback loop exists between cells of the immune system and resident 
epithelial cells in psoriasis. Regulatory T cells affect the vascular endothelial growth factor 
(VEGF)-related angiogenic microenvironment
58
 and contribute to hallmark features of 
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psoriasis such as epidermal hyperplasia.
59 Psoriasis is a systemic inflammatory disorder that 
involves complex pathogenic interactions between the innate and adaptive immune system 
that can be targeted by innovative biological therapies.
51 
 
 
Pathogenesis of allergic contact dermatitis 
Allergic contact dermatitis (ACD) is a common inflammatory skin disease presenting with 
pruritic, eczematous lesions. ACD results from a T cell-mediated, delayed type 
hypersensitivity (DTH) reaction elicited by the contact of the skin with allergens 
(haptens).
60,61
 Contact allergens are low molecular weight (<500 Daltons) chemicals called 
haptens, which are able to penetrate the stratum corneum barrier of the skin. Haptens are not 
immunogenic by themselves, but they can be efficiently recognized by the immune system 
after binding to a skin protein carrier. Haptens may be naturally occurring substances such as 
urushiol found in the resin of poison ivy, synthetic compounds, dyes, fragrances, drugs, or 
heavy metal salts. Haptens activate Toll-like receptors (TLRs) and activate innate 
immunity.
62-64
 Keratinocytes are crucial for the development of ACD. They constitute the 
vast majority of cells in the epidermis and form the anatomic barrier of the skin, expressing 
most TLRs, and this allows them to respond to TLR4-triggering haptens, such as nickel.
60 
Keratinocytes are also a source of IL-10, an immunosuppressive cytokine that limits the 
extent of contact hypersensitivity.
65 
ACD is a type IV of  DTH reaction that activates antigen-
specific T cells in a sensitized individual. The sensitized T cells are primarily T-helper 1 
(TH1) type.
60
 In the sensitization phase, innate immunity is activated through keratinocyte 
release of interleukin (IL)-1α, IL-1β, TNFα, granulocyte-macrophage colony-stimulating 
factor, and ILs-8 and -18. Langerhans and dermal dendritic cells uptake the allergen and 
migrate to the regional lymph nodes to activate antigen-specific T cells (ie, TH1, TH2, TH17, 
and regulatory T [Treg] cells).
60,65
 These T cells then proliferate and enter the circulation and 
13 
 
site of exposure. When re-exposed to the allergen, antigen-specific T cells are activated 
through the release of cytokines and induce an inflammatory process. Dermal dendritic cells, 
as opposed to epidermal Langerhans cells, play an important role in educating naïve T cells 
in the lymph node to become antigen-specific effector cells during cutaneous sensitization.
66
 
The histopathologic findings are different in acute and chronic contact dermatitis and are 
dependent on the severity of the inflammatory reaction. The most common histologic feature 
is spongiosis, which results from intercellular edema. It is often limited to the lower 
epidermis but, if the reaction is severe, it may affect the upper layers.
60 
 
 
 
Patch testing is the criterion standard in the diagnosis of ACD. Patch testing attempts to 
recreate, in vivo, an allergic reaction to nonirritating concentrations of an allergen that is 
suspended in a vehicle. Nickel is the most common cause of ACD in women in almost all 
14 
 
countries. The greater exposure of women to high-nickel content jewelry is a predisposing 
factor. Recent advances in knowledge of the mechanisms by which haptens can generate a 
specific T cell activation leading to ACD have reinforced the importance of hapten 
presentation by Langerhans cells to specific T cells.
67
 The induction of ACD depends on the 
production by epidermal cells, within minutes or hours following hapten application, of a 
rather specific pattern of cytokines. Indeed, previous study highlighted the complexity of the 
involvement of pro-inflammatory agonist and antagonistic members of the IL-1 family in the 
pathogenesis of ACD.
43
 
 
Pathogenesis of polymorphic light eruption 
Polymorphic light eruption (PLE; "i.e., sun allergy") is an inflammatory skin condition 
considered as the most common idiopathic photodermatosis, with a prevalence of up to 21% 
in temperate climates, particularly among young women.
68-70
 Although women are affected 
much more often,
71,72
 men also do develop the condition in significant numbers.
73
 PLE 
lesions usually appear in spring or early summer.
70,74
 Several morphological variants of PLE 
have been described, including papular, papulovesicular, plaque-type. The  affected body 
sites are sun-exposed areas, particularly those that are normally covered during the winter 
such as the upper chest, the neck and the extensor aspects of the arms.
75
 Many individuals 
experience a hardening effect with prolonged sun exposure, occurring after repetitive 
exposures to UV radiation.
74 
This means that, as summer progresses, skin lesions are less 
likely to occur, or may be less severe than they were in early spring allowing prolonged sun 
exposure. Previous studies revealed that most PLE patients are sensitive to UVA, but lesions 
can also be induced with UVB alone, and some patients are sensitive to both waveband 
ranges.
75,76
 The pathogenesis of PLE remains unclear: a genetic susceptibility has been 
identified as well as environmental components.
73,77
 PLE is thought to be a delayed-type 
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hypersensitivity response (DTHR) against putative ultraviolet (UV)-induced de novo 
antigens, allowed to develop by a characteristic inadequate UV-induced immune-
suppression.
78,79
 The delayed reaction time to UV radiation in PLE resembles that observed 
in immune responses mediated by CD4+ cells. A critical factor in the pathogenesis of PLE is 
the effect of UV light on skin components.
79-81
 It was hypothesized that in genetically 
predisposed subjects UV light induces a modification of certain skin molecules that renders 
them immunogenic. Supporting this hypothesis is the observation that cultured epidermal 
cells from PLE patients are capable of stimulating autologous peripheral blood mononuclear 
cells after exposure to high doses of UVA or UVB, suggesting that an immune sensitization 
against autologous UV light-modified skin antigens occurs in PLE.
82 
It is well known that the 
UV-induced suppression generates T cell-mediated responses in normal subjects involves the 
release of cytokines, particularly tumor necrosis factor (TNFα), interleukin (IL)-4 and IL-10, 
and the migration of Langerhans cells (LCs) out of the epidermis.
83
 Conversely, PLE patients 
has a failure of UV-induced immunosuppression, which may favor the occurrence of 
autoimmunogenic skin rashes.
78 
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In healthy individuals, LCs disappear from the  epidermis after UVB irradiation.
83
 IL-1β, 
TNF-α, and IL-18 release can modulate LC migration out of the skin.84It was demonstrated 
that after a single high dose of UVB radiation much less LCs were depleted from the 
epidermis of PLE patients compared with healthy controls.
78,79
 Moreover, neutrophils 
infiltration and suppressor macrophages  recruitment is significantly decreased in patients 
with PLE after UVB exposure,
78
 as well as T-regulatory limphocytes and related 
immunoregulatory factors after UVA1 irradiation.
85
 Because the incidence of UVB-
susceptibility was significantly higher in skin cancer patients, if patients with PLE have a 
general increased resistence to UV-induced, these patients could be more resistant to UV 
17 
 
carcinogenesis. This is supported by the results of our recent study (by Lembo et al.) that  
investigated the link between PLE and skin cancer.
86
 Koelgen et al
79
 compared the expression 
of UVB-induced cytokines in the skin of normal individuals with PLE skin and their results 
showed that the skin of PLE  patients contains lower levels  of cytokines related to LC 
migration (IL-1, IL-18 and TNF-alpha).  
The selection of the appropriate PLE treatment requires knowledge of the individual clinical 
course of the disease and depends on the frequency, duration and severity of the disease and 
the degree of lifestyle affection.
87,88
 Topical corticosteroids and occasionally oral 
antihistamines reduce the inflammation, alleviate itch and can shorten the duration of the 
eruption.
74,88 
Most PLE patients benefit from prophylactic treatment with phototherapy or 
photochemotherapy (hardening) to alleviate discomfort and lifestyle restrictions during the 
summer months or vacation periods in areas with high intensity sun exposure.
89 
 
 
III Chapter 
Experimental Design 
Objective: 
Our aim was to investigate on possible IL-36 involvement in some of most common 
inflammatory skin diseases such as, PSO, ACD and PLE.  
 
Materials and methods  
Study population 
Our study population comprised: PLE patients, ACD patients, PSO patients and healthy 
controls. PLE patients were enrolled from the general dermatology or the photodermatology 
clinic of the University of Naples Federico II. The diagnosis of PLE was verified by patient's 
history, clinical symptoms, histological findings, specific laboratory studies (absence of 
18 
 
antinuclear antibodies etc.) and/or phototesting procedures. Each patient was required to 
answer a questionnaire designed from a previous version used for a former PLE study,
 
aimed 
at establishing personal and family history of photodermatoses. Moreover, PLE severity of 
the last 12 months was measured through the PLE severity index (PLESI) questionnaire, on a 
10 to 100 arbitrary scale. ACD patients were enrolled from the dermato-allergology center 
computer-based database of our Clinic. Inclusion criteria were age ≥18 years and the 
presence of at least one relevant positive reaction to patch test. The intensity of reactions 
were evaluated according to the guidelines of the Italian Society of Allergological, 
Occupational and Environmental Dermatology (SIDAPA). Results were recorded as 
negative, doubtful, and positive with 1+, 2+, 3+, respectively, for positive weak, moderate 
and strong reaction. PSO patients were recruited from the database of patients attending the 
psoriasis center of University of Naples Federico II, Naples, Italy. Inclusion criteria were 
diagnosis of moderate to severe psoriasis [Psoriasis Area and Severity Index (PASI) > 10] 
(with or without psoriatic arthritis) made by a dermatologist, disease duration of at least 6 
months, topical and/or systemic treatment washout period of at least 3 weeks and age ≥18 
years. Moreover, additional lesional skin biopsies were also performed in 10 out of 20 
psoriatic patients after 16 weeks of treatments with anti-TNF-α (adalimumab) treatment. 
Control skin was obtained from surgical remnants of healthy donors undergoing 
abdominoplastic, with no history of photodermatosis, skin cancer or on-going inflammatory 
skin disease. The study was conducted according to the Declaration of Helsinki principles. 
The local ethical committee approved the study, and each participant gave written informed 
consent before entering the study. 
Phototesting procedures  
In all PLE patients, both UVA and UVB minimal erythema dose (MED) were obtained from 
untanned areas of the lower back by means of the Solar Simulator Multiport 601 (Solar Light 
19 
 
Company, Philadelphia, PA, USA). As indicated by the European Dermatology Guideline for 
the photodermatoses, provocative phototests with UVA and UVB were performed on a 
healthy and untanned area of the back or arms with the following procedure: a 5-10 cm
2
 
selected area was divided into three parts: the first one was irradiated with UVA only (metal 
halide lamp equipped with H1 and H2 filters, Dr Honle, Munich, Germany); the second one 
with UVB radiation only (TL12 fluorescent lamps, Philips, Amsterdam, the Netherlands) and 
the third one was irradiated with both UVA and UVB wavelengths. Irradiance measurement 
was performed before each irradiation session using an Il-1700 radiometer (Technology 
Drive, Peabody, Massachusetts, USA). The total dose given daily over 3–5 consecutive days 
was of 50-120 m J/cm
2
 UVB (corresponding to 0.75–1.5 of the calculated UVB MED) and 
30 J/cm
2
 of UVA.  The results were read at 2, 5, 7 up to 10 days. 25-27
    
Phototests resulted 
negative in 64.7% (n=11/17) and positive in 35.3% (n=6/17) of the examined patients. In 
particular: palpable erythema after UVA was appreciated in 11.8% (n=2/17) with similar 
reaction observed also adding UVB to the UVA wavelength, but not after specific UVB 
irradiation. Conversely UVB reactivity was observed in 17.6% (n= 3/17) with similar 
reaction also obtained after stimulation with UVB and UVA. One patient (5.9%) reacted only 
to the mixed irradiation (UVB+ UVA). 
 
 
Patients biopsies, RNA extraction, cDNA synthesis and real-time polymerase chain 
reaction (rt-PCR) 
Skin biopsies from PLE, ACD, PSO and healthy controls were collected. In the PLE and PSO 
patients, the biopsies were taken from spontaneous lesion observed during clinical 
assessment. Conversely, in the ACD patients, skin samples were taken from the positive 
reaction to the patch test. RNA was extracted (RNeasy Mini Protocol, Qiagen Valencia,CA) 
and cDNA was prepared (Transcriptor High Fidelity cDNA Synthesis, Roche, Indianapolis, 
20 
 
IN) according to the manufacturer’s instructions. rt-PCR (LightCycler, Roche, Indianapolis, 
IN) was used to analyze the levels of expression of 18S, IL-36Ra, IL-36α, IL-36β, IL-36γ. 
Each PCR was performed 2 times, each time in triplicate. PCR protocol and product 
quantification for 18S ribosomal RNA were performed as reported previously.28 PCR primers 
for the selected genes were designed based on published sequences and their specificity was 
verified with BLAST alignment search. To confirm amplification of the expected size 
fragment, products were characterized by agarose gel electrophoresis. Melting curve analysis 
was carried out after completion to confirm the presence of single amplified species. The 
amount of mRNA for a given gene in each sample was normalized to the amount of mRNA 
of 18S reference gene in the same sample. Fold induction of gene expression was calculated 
using the CT method. Results obtained from each PCR were pooled and statistically 
analyzed. 
In vivo expression of IL-36 in the skin  
Skin biopsies (3 mm) were collected from involved sites of subjects affected by PLE (n=17), 
psoriasis (n=20), ACD (n=10) as well as from normal skin of healthy control subjects (n=15) 
for in vivo mRNA examination through real-time PCR.  
In vivo expression of IL-36 in psoriasis subjects before and after anti-TNF-α treatment 
Skin biopsies (3 mm) from involved sites of 10 out of 20 psoriatic patients were collected 
before (week 0) and after 16 weeks of anti-TNF-α (adalimumab) treatment for in vivo mRNA 
examination through real-time PCR. Adalimumab was administered subcutaneously 80 mg at 
week 0 (baseline) and successively 40 mg every other week starting from week 1 and up to 
week 16. 
Immunohistochemical detection of IL-36 family members  
The immunohistochemical detection of IL-36 family members was carried out on the skin 
biopsies from the lesions of PLE, ACD, PSO patients and healthy controls. Skin samples 
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were immediately placed in tissue freezing medium (Jung, Leica, Wetzlar, Germany) and 
stored at −80° C. Five micrometer sections were cut with a cryostat and fixed with cold 
acetone for 10 min. The Vectastain Elite ABC Kit (Vector Laboratories, Burlingame, CA) 
was used as follows: sections were incubated with blocking solution (horse serum diluted in 
buffer: phosphate buffered saline [PBS] + bovine serum albumin 1%) for 20 min at 22°C. 
Some slices were initially stained with haematoxylin (Fisher Scientific, Pittsburgh, PA, 
U.S.A.) and eosin (Shandon, Pittsburg, PA, U.S.A.) for morphological evaluation. Thereafter, 
staining for IL-36α (15 μg/ml R&D System Inc, Minneapolis, MN), IL-36β (5 μg/ml R&D 
System Inc, Minneapolis, MN), IL-36γ (15 μg/ml R&D System Inc, Minneapolis, MN) and 
IL-36Ra (5 μg/ml R&D System Inc, Minneapolis, MN) was performed, incubating tissue 
sections at 4°C overnight. In parallel, other sections were incubated with specific isotype 
control antibodies (Mouse IgG1-2B Isotype Control,  Goat IgG Control, R&D System Inc, 
Minneapolis, MN) used at the same concentration as the corresponding primary antibody. All 
the sections were then washed in buffer and incubated with biotinylated secondary antibody 
for 30 min at room temperature. Peroxydase activity was revealed using DAB substrate 
(ImmPACT DAB, Burlingame, CA). Counterstaining was performed with hematoxylin. For 
grading the staining intensity, the T-MARKER (http://comp-path.inf.ethz.ch) image analysis 
software was used according to the standardized protocol.30 Mean intensity values of all 
analyzed interleukins were calculated for each patient and control. 
IL-36γ serum levels in psoriasis, ACD and healthy control subjects 
Blood samples were taken from the subjects affected by psoriasis (n=20) and ACD (n=10) as 
well as healthy control subjects (n=10)  for the determination of IL-36γ concentrations by 
single enzyme-linked immunosorbent assay (ELISA). Commercially available kit (Uscn, Life 
Science, Inc.) was used according to the manufacturer’s instructions. 
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Supernatants collected from healthy skin organ culture, performed as previously 
described,
37
stimulated with TNF-α (20ng/ml) for 24h were used as positive controls. These 
supernatants were checked for the presence of IL-36γ by western blot analysis too and a 
significant increase was detected after TNF-α treatment. 
IL-36γ serum levels in PLE patients  
Blood samples were collected by venepuncture, into plain collection tubes for serum, from 
PLE patients and controls. Extracted serum proteins were loaded (20 µg of proteins) on the 
10% Bis-Tris NuPage denaturing gel (Invitrogen Life Technologies, Carlsbad, CA) for 
electrophoresis. Gels were transferred to  nitrocellulose  membranes  and  were  probed  with  
IL-36 γ monoclonal antibody (R&D System Inc, Minneapolis, MN);  detection performed 
with  WesternDot™  625 western  blot detection  kit  (Invitrogen  Life  Technologies,  Grand  
Island,  NY).  The enhanced  fluorescent bands  were assessed using  Gel-Doc  densitometer  
and  Quantity-One  software  (Bio-Rad, Hercules,  CA).   
In vitro expression of IL-36γ in peripheral blood mononuclear cells (PBMC) 
PBMC were isolated from subjects affected by psoriasis (n=5) and ACD (n=5) as well as 
healthy control subjects (n=5)  by density gradient centrifugation over Ficoll-Paque Plus (GE 
Healthcare, Uppsala, Sweden). Cell number and viability were determined using Trypan blue 
test. mRNA was extracted from 1x10
6 
cells for examination through real-time PCR.  
In vitro expression of IL-36γ in stimulated PBMC 
PBMC isolated from 5 healthy controls, 5 psoriatic and 5 nickel-ACD (#1-5) patients were 
cultured in Roswell Park Memorial Institute (RPMI; GIBCO) medium, supplemented with 
antibiotics (100 IU/ml penicillin G and 100 lg/ml streptomycin; GIBCO) and 10% FBS 
(GIBCO), at a concentration of 2 x 10
6
 in 12-well plates. They were stimulated with 5μg/ml 
of concanavalin A (ConcA) (Sigma-Aldirich, Oakville, ON, Canada) or 100ng/ml of toxic 
shock syndrome toxin (TSST-1) (Sigma-Aldirich, Oakville, ON, Canada) or 10
-4
M of NiSO4. 
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They were incubated for 24 hours at 5% CO2 at 37°C. mRNA was extracted for examination 
through real-time PCR. 
Ex vivo expression of IL-36γ in ACD non lesional skin assay 
4 skin biopsies (3 mm each) from each of 5 nickel-ACD (#1-5) patients and 4 skin biopsies 
(3mm each) from each of 5 healthy subjects who had undergone plastic surgery were 
performed to execute ex vivo ACD assays. Skin biopsies of nickel-ACD patients were taken 
from uninvolved sites. Biopsies were cultured as follows: a hole was punched in a transwell 
filter (pore size 1 μm; Beckton Dickinson Labware, Franklin Lakes, NJ); the biopsy was 
inserted into the hole, and the filter containing the biopsy was placed in a 12-well culture 
plate (Beckton Dickinson Labware) containing 1 ml of Dulbecco’s modified Eagle’s medium 
(DMEM, GIBCO, Grand Island, NY) containing 10% FBS (GIBCO), 2 mM L-glutamine 
(GIBCO) and antibiotics (100 IU/ml penicillin G, 100 μg/ml streptomycin, GIBCO). In this 
way the epidermis faces upwards at the liquid-air interface whereas the dermis is suspended 
in the culture medium. The 4 skin biopsies (both of nickel-ACD and healthy subjects)  were 
treated as follows: i) 1 skin biopsy was cultured only with medium and used as control, ii) 1 
skin biopsy was exposed to the allergen that had previously elicited the positive patch test 
reaction (NiSO4), iii) 1 skin biopsy was exposed to NiSO4 and contemporarily PBMC 
isolated from the same subjects were added to the multiwell (not into the  transwell filter), iv) 
1 skin biopsy was cultured with medium and contemporarily PBMC isolated from the same 
subjects were added to the multiwell (not into the  transwell filter). This system was 
incubated for 72 hours at 5% CO2 at 37°C. The quantity of NiSO4 (5% in petrolatum) used 
for these assays (30 mg) was the same used for the patch tests. After 72 hrs mRNA was 
extracted from PBMC, separately collected, and from cultured skin biopsies for examination 
through real-time PCR.  
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Statistical analyses 
Data that passed the normality test were analyzed with two-tailed, t test, otherwise Wilcoxon 
test was used to calculate statistical differences. P values <0.05 were considered statistically 
significant. *p<0.05; **p<0.01; ***p<0.001.All statistical analyses were performed using 
GraphPad Prism 4.0 (GraphPad Software Inc, La Jolla, CA).  
 
 
 
 
Results 
 
 
IL-36 cytokines gene expression in lesional skin  
As showed in Fig.1, gene expression of IL-36α and IL-36γ was significantly increased in 
PLE skin compared to healthy controls (HS). Conversely IL-36β, IL-36Ra and IL-33 did not 
increase in PLE skin. In ACD as well as PSO, all analyzed interleukins were significantly 
increased, except for  IL-36 receptor antagonist (IL-36Ra) in ACD. IL-36γ was expressed at 
higher level in PLE skin rather than PSO and ACD skin. 
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Figure 1. IL-36 expression in lesional skin: mRNA fold expression of IL-36 (α, β, γ) and IL-36Ra (Ra) in 
healthy control (HS), PLE , PSO and ACD skin biopsies. PCR values are expressed as fold increase expression 
normalized to the housekeeping gene 18S respect to control skin from normal donors. Data are displayed as 
mean± standard deviation (SD); *p<0.05; **p<0.01;***p<0.001 
 
 
Immunoistochemical detection of IL-36 cytokines 
In addition, we also evaluated IL-36 cytokines at protein level by IHC in PLE, PSO and ACD 
patients compared to healthy skin samples. IL-36 agonists resulted enhanced in all 3 analyzed 
diseases. In particular the increase was more marked and diffuse through the epidermal layers 
in ACD and PSO samples, whereas it resulted moderate and mainly localized to granular and 
spinous layers in PLE. Results of the TMARKER image analysis of staining intensity 
confirmed immunoistochemical data. 
 
 IL-36Ra 
(Mean ± SEM) 
IL-36α 
(Mean ± SEM) 
IL-36β 
(Mean ± SEM) 
IL-36γ 
(Mean ± SEM) 
PLE  4.2 ± 0.84 48.0 ± 1.08 41.0 ± 3.82 74.0 ± 4.12 
PSO 4.5 ± 1.0 57.3 ± 1.86 42.31 ± 2.56 74.8± 2.98 
ACD  5.1 ± 0.41 55.0 ± 2.08 45.0 ± 1.23 72.7 ± 3.15 
HS 1.72 ± 0.17 3.33 ± 1.84 16.35 ± 0.32 4.51 ± 0.13 
 
Table 1. TMARKER results: Immunohystochemistry staining intensities. Statistical significance calculated 
over staining in the control skin. SEM: standard error of the mean. 
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Figure 2. IL-36 protein expression in lesional skin: Immunohistochemical detection of IL-36 (α, β, γ) and IL-
36Ra in skin biopsies of PLE, PSO, ACD patients and healthy donors (HS). Each picture is representative of 
data from 15 different patients affected by PLE, ACD and 10 normal donors. 
 
 
 
Anti-TNF-α treatment decreases IL-36 gene expression in psoriatic skin 
An efficacious anti-TNF-α treatment is able to downregulate significantly (*p<0.05; 
**p<0.01) all the pro- and anti-inflammatory members of IL-36 subfamily, except for IL-
36β. 
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Figure 3. Anti-TNF-α treatment modulates IL-36 gene expression: mRNA fold expression of IL-36 (α, β, γ) 
and IL-36Ra (Ra) in lesional skin of 10 psoriasis patients before and after 16 weeks of anti-TNF-α treatment. 
PCR values are expressed as fold increase expression normalized to the housekeeping gene 18S respect to 
control skin from normal donors. Data are displayed as mean± standard deviation (SD); *p<0.05; 
**p<0.01;***p<0.001 
 
 
IL-36γ serum levels in psoriasis, ACD and healthy control subjects 
Next, we analyzed IL-36γ serum levels in ACD and PSO patients and no significant 
differences were found, even when comparing with healthy controls. This result was 
confirmed by the presence of a positive control checked by western blot analysis too. 
Supernatants collected from healthy skin organ culture, performed as previously described,
37 
stimulated with TNF-α (20ng/ml) for 24h were used as positive controls. These supernatants 
were checked for the presence of IL-36γ by western blot analysis too and a significant 
increase was detected after TNF-α treatment.  
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Figure 4. IL-36γ serum levels: HC (n=10), PSO (n=10) and ACD (n=10) subjects. Supernatants from healthy 
skin organ culture treated with TNF-α (20ng/ml) for 24h are used as positive controls (CTRL+). Data are 
displayed as mean± standard deviation (SD); 
 
Western blot analysis of IL-36γ 
Since we have detected the highest increase among all analyzed conditions for IL-36γ in 
PLE, we sought to better explore this cytokine also at serum level. A significant enhance was 
found compared to healthy donors, in contrast to other skin inflammatory conditions as above 
showed. 
 
 
 
 
29 
 
   
 
 
Figure 5. IL-36γ protein levels in PLE patients: A) Representative western blot image analysis of IL-36γ in 
PLE patients and healthy controls. B) Densitometry is plotted as adjusted volume density (intensity mm
2
)  
 
 
IL-36γ expression in peripheral blood mononuclear cells (PBMC) 
We checked for IL-36γ gene expression in circulating  PBMC isolated from psoriatic and 
ACD patients as well as healthy controls, with no significant differences found (Fig.6A). 
Additionally, in order to further elicit a response, PBMC isolated from healthy subjects, 
psoriatic and nickel-ACD patients were exposed in vitro to concanavalin A (ConcA), toxic 
shock syndrome toxin (TSST-1) and to nickel sulphate (NiSO4). Only the stimulation with 
NiSO4 in ACD PBMC was able to induce a significant increase (*p<0.05) of IL-36γ respect 
to healthy controls (Fig.6B).  
 
 
 
 
 
 
 
 
A                                                                                            B              
IL-36γ 
30 
 
 
 
 
 
Figure 6. In vitro expression IL-36γ: A) IL-36γ gene expression in PBMC of HC (n=5), PSO (n=5) and ACD 
(n=5) subjects. B) IL-36γ gene expression in stimulated PBMC with concanavalin A (ConcA; 5µg/ml), toxic 
shock syndrome toxin (TSST-1; 100ng/ml) and nickel (NiSO4; 10-4M) for 24 hours. 
 
 
Ex vivo expression of IL-36γ in ACD non lesional skin assay 
At this point, we wanted to highlight IL-36γ involvement in ACD and ex vivo ACD non 
lesional skin assay was performed. IL-36γ expression was significantly augmented in 
uninvolved ACD skin when treated with the allergen (NiSO4), but an even more enhanced 
increase was obtained in uninvolved ACD skin when PBMC were added to the system. 
 
 
 
 
 
 
 
 
A                                                                      B 
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Figure 7. Ex vivo non lesional skin assay: IL-36γ gene expression in healthy skin (HS; n=5) and in non 
lesional (NLes) nickel-ACD skin (n=5) stimulated with 30mg of NiSO4 (5% in petrolatum). PBMC isolated 
from the same subjects were incubated in the system with or without NiSO4.  
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IV CHAPTER 
Discussion 
Over recent years much has been learned on IL-36 cytokines about their important functions 
in the regulation of immune response and, especially, on their involvement in many 
inflammatory conditions.
21,22,27,36
 In this study, we wanted to elucidate the role of these 
mediators in some of the most common skin inflammatory diseases, evaluating their levels in 
psoriasis, ACD and PLE. We found that the increase of all 3 agonist members was more 
evident respect to receptor antagonist. Recently, D’ Erme et al. have reported IL-36γ as 
having a highly specific positive predictive diagnostic value for psoriasis.
90
 This is in part 
true, also according to our data, even though we strongly believe that IL-36 agonists are 
involved not only in psoriasis, but also in ACD as well as PLE. We shown that IL-36α, IL-
36β, and IL-36γ are enhanced in ACD and PSO skin too.36,43 We speculate that they might 
represent markers of skin inflammation in general, and it seems weakly reliable that IL-36γ 
alone might constitute a specific psoriasis marker. We have performed a comparison for skin 
IL-36 gene expression in the 3 examined disorders was performed, with a significant 
increase, respect to healthy subjects, for all members, except for IL-36 receptor antagonist 
(IL-36Ra) in PLE as well as ACD. These results were confirmed at protein level by 
immunohistochemical analysis of skin biopsies. Indeed, IL-36 members resulted enhanced in 
3 all analyzed diseases compared to healthy skin, except for IL-36Ra. This last one is the 
anti-inflammatory member of IL-36 sub-family and the lack of the natural antagonist in ACD 
let us to hypothesize that the activity of IL-36α, IL-36β and IL-36γ is‘unopposed’and 
therefore that these cytokines can drive skin inflammation.
43 Nevertheless, we found that IL-
36γ was expressed at higher level in PLE as well as psoriatic skin rather than ACD skin. This 
finding was in agreement with Quaranta et al.,
91
 who found a significant increase of IL-36γ 
both in psoriatic and eczematous skin, with a main up-regulation in psoriasis. The impact of 
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an anti-TNF-α treatment on psoriatic skin levels of IL-36 (α, β and γ) and IL-36Ra was 
evaluated, with significant decrease for all analyzed interleukins, except for IL-36β. This data 
reflects the fact that an efficacious treatment is able to downregulate all the pro- and anti-
inflammatory members of IL-36 subfamily, indiscriminately. Next, we analyzed IL-36γ 
serum levels in 2 categories of patients (PSO; ACD) and no significant differences were 
found, even when comparing with healthy controls; this result was confirmed by the presence 
of a positive control checked by western blot analysis too. Furthermore, we assessed serum 
IL-36γ levels by western blot in PLE patients too. Conversely, we found an increase of IL-
36γ circulating cytokine in PLE compared with healthy controls. This data could confirm the 
presence of a systemic inflammation of these patients. Wolf et al. reported that PLE patients 
had a significantly higher baseline plasma level of  pro-inflammatory cytokines.
85 Next, we 
analyzed IL-36γ gene expression in circulating peripheral blood mononuclear cells (PBMC) 
isolated from psoriatic and ACD patients as well as healthy controls, with no significant 
differences found. Moreover, in order to further elicit a response, PBMC isolated from 
healthy subjects, psoriatic and nickel-ACD patients were exposed in vitro to concanavalin A 
(ConcA), toxic shock syndrome toxin (TSST-1) and to nickel sulphate (NiSO4). Only the 
stimulation with NiSO4 in ACD PBMC was able to induce a significant increase of IL-36γ 
respect to healthy controls, suggesting that this IL might be involved in ACD too. At this 
point, we wanted to highlight IL-36γ involvement in ACD and ex vivo ACD non lesional skin 
assay was performed. IL-36γ gene expression was significantly augmented in uninvolved 
ACD skin when treated with the allergen (NiSO4), but an even more enhanced increase was 
obtained in uninvolved ACD skin when PBMC were added to the system. In order to deeply 
comprehend the contribution given by PBMC, we compared IL-36γ gene expression as well 
as of its known inducers (TNF-α and IL-1α) in nickel-ACD PBMC treated in vitro with 
NiSO4 and nickel-ACD PBMC incubated in ex vivo ACD non lesional skin assay. A 
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significant increase was detected for all ILs in PBMC that had been incubated in the skin 
system. 
Indeed, it is well known that skin inflammation results from the multipartite interactions of, 
at least, keratinocytes (KCs), T cells and antigen presenting cells (APCs). In this scenario 
KCs are the major source of IL-36γ which contributes to skin inflammation by acting on 
KCs, APCs and indirectly upon T cells driving tissue infiltration, cell death and 
proliferation
25,92
; Tortola et al., 2012). We speculate that in ex vivo ACD non lesional skin 
system, IL-36γ produced by KCs promotes skin T cells infiltration amplifying cutaneous 
damage with an increase in IL-36γ. The expression of IL-36γ is highly complex and it may 
have distinct functions dependent upon the context in which it is expressed. It is reported that 
IL-36γ acts as an alarmin, being up-regulated by toll-like receptor ligand expressed in 
response to the innate immune system activation and having a central position in pro-
inflammatory pathways at the interface between innate and adaptive immunity.
93
  
Furthermore, IL-36γ induces the production of several proinflammatory cytokines, including 
IL-12, IL-6, TNF-α, and IL-23,41 involved both in psoriasis and ACD. All these evidences 
support our hypothesis that IL-36γ could represent a marker for skin inflammation and not a 
specific one for psoriasis. 
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